The FDA approved a 10 mg immediate-release tablet of RoxyBond for pain management in situations where other treatments are inadequate. This oxycodone hydrochloride formulation, manufactured by Protega Pharmaceuticals, is the first 10 mg abuse-deterrent immediate-release oxycodone approved by the FDA. Using the SentryBond abuse-deterrent technology, RoxyBond offers multiple levels of protection against physical and chemical manipulation for injection. While resistant to cutting, crushing, grinding, and extraction, it is still possible for abuse to occur through intranasal, oral, and IV routes. Protega aims to combat prescription opioid abuse and misuse by developing innovative technology for potential application in other medications.
Source link
FDA approves new dose for abuse-deterrent oxycodone
